uniQure (NASDAQ:QURE) Sets New 1-Year High – What’s Next?

uniQure (NASDAQ:QURE)’s share price reached a new 52-week high during trading on Monday . The stock traded as high as $17.95 and last traded at $17.71, with a volume of 450937 shares. The stock had previously closed at $16.98.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the company. Wells Fargo & Company raised uniQure from a “hold” rating to a “strong-buy” rating in a report on Tuesday, December 10th. Royal Bank of Canada raised their target price on shares of uniQure from $14.00 to $20.00 and gave the company an “outperform” rating in a research note on Wednesday, December 11th. Mizuho boosted their price target on shares of uniQure from $7.00 to $20.00 and gave the stock a “neutral” rating in a research note on Thursday, December 19th. The Goldman Sachs Group raised their price objective on shares of uniQure from $9.00 to $20.00 and gave the company a “neutral” rating in a research report on Thursday, December 12th. Finally, Raymond James upgraded shares of uniQure from an “outperform” rating to a “strong-buy” rating and upped their target price for the stock from $20.00 to $52.00 in a research report on Tuesday, December 10th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, uniQure currently has a consensus rating of “Moderate Buy” and a consensus price target of $33.88.

uniQure Stock Performance

The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92. The company has a market cap of $845.69 million, a P/E ratio of -3.50 and a beta of 0.89. The company’s fifty day moving average is $8.36 and its 200 day moving average is $6.86.

uniQure (NASDAQ:QURE) last announced its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.12) by $0.21. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. The firm had revenue of $2.29 million for the quarter, compared to analysts’ expectations of $2.73 million. As a group, equities analysts predict that uniQure will post -3.82 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other uniQure news, CEO Matthew C. Kapusta sold 3,418 shares of the stock in a transaction on Monday, December 9th. The shares were sold at an average price of $7.63, for a total transaction of $26,079.34. Following the completion of the sale, the chief executive officer now owns 597,915 shares of the company’s stock, valued at $4,562,091.45. This represents a 0.57 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 4.74% of the company’s stock.

Hedge Funds Weigh In On uniQure

Several hedge funds and other institutional investors have recently modified their holdings of the company. SG Americas Securities LLC purchased a new position in uniQure during the 2nd quarter valued at about $79,000. Privium Fund Management B.V. increased its stake in shares of uniQure by 10.6% during the second quarter. Privium Fund Management B.V. now owns 640,416 shares of the biotechnology company’s stock valued at $2,869,000 after buying an additional 61,501 shares during the period. Doheny Asset Management CA bought a new position in shares of uniQure during the second quarter valued at approximately $1,220,000. American Century Companies Inc. lifted its stake in uniQure by 14.6% in the second quarter. American Century Companies Inc. now owns 67,699 shares of the biotechnology company’s stock worth $303,000 after acquiring an additional 8,642 shares during the period. Finally, Total Clarity Wealth Management Inc. bought a new stake in uniQure in the second quarter valued at $74,000. 78.83% of the stock is owned by institutional investors.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.